demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis (AD) significantly reduced patients’ reliance on other topical treatments, oral corticosteroids, and biologics in ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on biologics, the patients with moderate-to-severe atopic dermatitis on Janus ...

The majority of patients with head and neck atopic dermatitis treated with tralokinumab experienced improvements in their Eczema Area and Severity Index scores. Tralokinumab yields nearly 90% disease ...

The expanding armamentarium of biologic therapies for patients with atopic dermatitis (AD) allows flexibility in treatment strategies for adolescents and adults. Current evidence indicates that ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

Researchers conducted a systematic review of 16 studies on the menstrual cycle and AD, following Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. The literature ...

Background: The relationship between atopic dermatitis (AD) and lymphoma risk remains debate. This study systematically evaluates lymphoma risk in AD patients compared to non-AD individuals. Methods: ...

For itching, take an oral antihistamine or apply cream. Watch for signs of infection in the following ... as soon as the cold sore develops in order for it to be effective. Atopic dermatitis is often ...

receptor pathway in moderate to severe atopic dermatitis (AD). SM17 uniquely binds to the co-receptor for IL-25, a key alarmin, and blocks downstream signaling - disrupting the inflammatory ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission. Raj Chovatiya ...

Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. A ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.